Medicine and Dentistry
Immune Checkpoint Inhibitor
100%
Biological Marker
75%
Molecular Imaging
66%
Neoplasm
62%
Gut Microbiome
50%
Zirconium 89
50%
Nodular Melanoma
50%
Pharmacokinetics
29%
Positron Emission Tomography-Computed Tomography
25%
Human Study
25%
Cancer Treatment
25%
Biodistribution
25%
Image Quality
25%
Nuclear Imaging
25%
Radioactive Tracer
25%
Monocyte Chemotactic Protein 2
25%
Clinical Research
25%
Immunotherapy
25%
Interleukin 6
25%
Scatter Factor
25%
Tomography
16%
Ipilimumab
16%
Positron Emission Tomography
16%
Microbiome
15%
Positron Emission Tomography
12%
Programmed Death-Ligand 1
12%
Monoclonal Antibody
12%
Clinical Trial
12%
Oncology
12%
Nivolumab
12%
Tumor Progression
12%
Progression Free Survival
11%
Cutaneous Melanoma
11%
Disease
8%
Patient Selection
8%
Clinical Study
8%
Immune Response
8%
Immunocompetent Cell
8%
Photomultiplier
8%
Meta-Analysis
6%
Overall Survival
6%
Inflammatory Cytokine
6%
Combination Therapy
6%
Malignant Neoplasm
6%
Pembrolizumab
6%
Study Subject
6%
Akkermansia muciniphila
5%
Roseburia
5%
Bifidobacterium pseudocatenulatum
5%
Reproducibility
5%
Keyphrases
Advanced Melanoma
50%
Immune Checkpoint Inhibitor Response
31%
Pharmacokinetics
25%
Cross-cohort
25%
Biodistribution
25%
Hepatocyte Growth Factor
25%
Immune Checkpoint Therapy
25%
Zirconium-89 (89Zr)
25%
ImmunoPET
25%
First-in-human Study
25%
Inflammatory Proteins
25%
Interleukin-6
25%
Gut Microbiome
25%
Monocyte Chemoattractant protein-1 (MCP-1)
25%
Immune Checkpoint Inhibitors
18%
Microbiome
18%
Ipilimumab
18%
Tumor Uptake
18%
Overall Response Rate
18%
Nivolumab
12%
Non-responders
12%
Online Treatment
12%
Immune Checkpoint Inhibitor Therapy
12%
Treatment Level
12%
Inflammation
12%
PD-L1 Expression
12%
Clinical Response
12%
Positron Emission Tomography
12%
Progression-free Survival
12%
SUVmax
12%
SUVmean
12%
Two-level
12%
Oncology Clinical Trials
8%
Immune Imaging
8%
Vision Data
8%
Molecular Imaging Biomarker
8%
Drug Target Engagement
8%
United Kingdom
6%
Pembrolizumab
6%
Observational Cohort
6%
Programmed Death-ligand 1 (PD-L1)
6%
Serum Samples
6%
Treatment Course
6%
Predictive Biomarker
6%
Bifidobacterium Pseudocatenulatum
6%
Roseburia
6%
Meta-analysis
6%
Tracer Uptake
6%
Advanced Cutaneous Melanoma
6%
Tumor
6%
Immunology and Microbiology
Molecular Imaging
75%
Gut Microbiome
50%
Positron Emission Tomography
43%
Pharmacokinetics
36%
Programmed Death-Ligand 1
25%
Cancer Immunotherapy
25%
Immunotherapy
25%
Cytotoxic T-Cell
25%
Immunocompetent Cell
16%
Positron
16%
Microbiome
15%
Cellular Distribution
10%
Metagenomics
10%
CD8
10%
Masking
8%
Ipilimumab
8%
Single Photon Emission Computed Tomography
8%
Immune Response
8%
T Cell
8%
Lymph Node
8%
Blood Plasma
8%
Lymphoid Organ
8%
Tumor Cell
8%
Immune System
8%
Overall Survival
5%
Bifidobacterium pseudocatenulatum
5%
Immunogenicity
5%
Pharmacodynamics
5%
Akkermansia muciniphila
5%
Adoptive Immunity
5%
Lymphoid Tissue
5%
Progression Free Survival
5%
Dynamics
5%
Mismatch Repair
5%
Sample Size
5%
Roseburia
5%
